BAMS
SGMO

Bellevue Asset Management (Switzerland)’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Bellevue Asset Management (Switzerland)’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-50,000
Closed -$555K – 137
2015
Q2 		$555K Hold
50,000
– – 0.08% 123
2015
Q1 		$784K Buy
+50,000
New +$774K 0.11% 122

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Bellevue Asset Management (Switzerland)'s SGMO Position: Q3 2015 in Review

Bellevue Asset Management (Switzerland) sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2015, closing a stake of 50,000 shares — an estimated $555K sold.

Bellevue Asset Management (Switzerland) first reported a position in SGMO in Q1 2015 and held it in 2 quarters. The position peaked at $784K in Q1 2015. 141 funds tracked by Wall St. Rank hold SGMO as of Q3 2015.

  • Bellevue Asset Management (Switzerland) reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2015 after selling out during the quarter.
  • Bellevue Asset Management (Switzerland) sold 50,000 SANGAMO THERAPEUTICS INC shares in Q3 2015, an estimated $555K.
  • Bellevue Asset Management (Switzerland) first reported a position in SANGAMO THERAPEUTICS INC in Q1 2015 and held it in 2 quarters.
  • Bellevue Asset Management (Switzerland)'s SANGAMO THERAPEUTICS INC position peaked at $784K in Q1 2015.
  • 141 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2015.

Based on Bellevue Asset Management (Switzerland)'s 13F filing for Q3 2015, filed 12 Nov 2015.